

# Meet the Challenges of Breast Cancer Testing

## One Assay Targeting Two Breast Cancer Biomarkers

Not all immunoassays are the same. Using the right immunoassay facilitates breast cancer management from monitoring therapeutic response to follow-up and early detection of recurrence.

Tosoh's ST AIA-PACK<sup>®</sup> 27.29 assay simultaneously targets both breast cancer biomarkers, CA27.29 (B27.29) and CA15-3 (DF3), each of which has been shown to play unique roles for disease monitoring in advanced breast cancer.

Choose wisely. Choose Tosoh.

### **Biotin-free**

No risk of bias from biotin interference from the widespread use of biotin supplements

### **Dry reagent**

90-day calibration stability

### **Proprietary Test Cup Technology**

Universal format for all our automated immunoassay analyzers

### **Rapid & Accurate**

Reliable results in 18 minutes



AIA-360



AIA-900



AIA-2000

**For more information, call 1.800.248.6764**

*Tosoh products are for Prescription use only as In-Vitro Diagnostics*

# TOSOH BIOSCIENCE

[www.tosohbioscience.us](http://www.tosohbioscience.us)

"Tosoh Bioscience", "AIA-PACK" and "AIA" are the registered trademarks of Tosoh Corporation  
Part # ADS-AIA-002



TOSOH